The Dasatinib Market refers to the global demand and supply of Dasatinib, a tyrosine kinase inhibitor used primarily in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It works by blocking the action of specific proteins that promote the growth of cancer cells, making it a targeted therapy. Dasatinib has revolutionized the treatment landscape for these types of leukemia by improving patient outcomes and offering an effective therapeutic option for patients who are resistant or intolerant to other treatments.